TY - JOUR T1 - L-[3-<sup>18</sup>F]-α-Methyltyrosine Accumulation as a Definitive Chemoradiotherapy Response Predictor in Patients with Esophageal Cancer JF - Anticancer Research JO - Anticancer Res SP - 909 LP - 913 VL - 34 IS - 2 AU - MAKOTO SOHDA AU - HIROAKI HONJYO AU - KEIGO HARA AU - DAIGO OZAWA AU - SHIGEMASA SUZUKI AU - NARITAKA TANAKA AU - AKIHIKO SANO AU - MAKOTO SAKAI AU - TAKEHIKO YOKOBORI AU - TAKANORI INOSE AU - TATSUYA MIYAZAKI AU - HITOSHI OJIMA AU - TETSUYA HIGUCHI AU - YOSHITO TSUSHIMA AU - HIROYUKI KUWANO Y1 - 2014/02/01 UR - http://ar.iiarjournals.org/content/34/2/909.abstract N2 - Aims: L-[3-18F]-α-Methyltyrosine (18F-FAMT) has high specificity for malignant tumors on positron emission tomography (PET), and its role and potential usefulness has been previously investigated in operable esophageal carcinoma. We aimed to assess the ability of 18F-FAMT PET to predict the response of esophageal cancer to definitive chemoradiotherapy. Patients and Methods: We retrospectively reviewed 40 patients with esophageal cancer imaged with 18F-FAMT PET. The relationship between 18F-FAMT PET uptake before chemoradiotherapy and clinical outcomes was assessed. Results: The primary tumor was visualized in 95% patients. 18F-FAMT uptake was significantly positively correlated with lymph node metastasis. The low-18F-FAMT accumulation group had significantly higher complete response (CR) rates than did the high-accumulation group. The addition of a lymph node metastasis category with low 18F-FAMT uptake provides a more precise predictor of CR. Conclusion: 18F-FAMT uptake prior to treatment is a good predictor of CR rate after CRT for esophageal cancer. ER -